Iguchi Fukuichiro, Taniguchi Zenchi, Kusano Junko, Takahashi Yuka, Murai Norihiko
Nihon Jibiinkoka Gakkai Kaiho. 2014 Aug;117(8):1108-14. doi: 10.3950/jibiinkoka.117.1108.
Salivary duct carcinoma is a malignant salivary neoplasm with a poor prognosis. Effective treatment for remote metastases has not been recognized. We report herein on a case of this tumor overexpressing HER2 successfully treated with trastuzumab-based molecular targeted therapy. The patient was a 69-year-old man, who developed remote metastases into the liver and the thoracic vertebra six months after surgery and postoperative irradiation for the primary and nodal lesions. After targeted therapy including paclitaxel and trastuzumab, these metastatic lesions showed rapid and continued regression. After paclitaxel was discontinued due to peripheral neuropathy in the extremities, trastuzumab monotherapy followed without resulting in cardiotoxicity. After three years since development of remote metastases, the patient is doing well without re-progression of the disease.
涎腺导管癌是一种预后较差的恶性涎腺肿瘤。目前尚未发现针对远处转移的有效治疗方法。我们在此报告一例过表达HER2的该肿瘤患者，经曲妥珠单抗为基础的分子靶向治疗成功治愈。患者为一名69岁男性，在对原发灶和区域淋巴结病变进行手术及术后放疗6个月后出现肝脏和胸椎的远处转移。在接受包括紫杉醇和曲妥珠单抗在内的靶向治疗后，这些转移病灶迅速且持续消退。由于四肢出现周围神经病变而停用紫杉醇后，继续进行曲妥珠单抗单药治疗，未出现心脏毒性。自出现远处转移三年以来，患者情况良好，疾病未再次进展。
